Insider Transactions in Q3 2024 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 21
2024
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,075
-0.36%
|
$29,025
$27.64 P/Share
|
|
Sep 21
2024
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
964
-2.18%
|
$26,028
$27.64 P/Share
|
|
Sep 21
2024
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
966
-1.22%
|
$26,082
$27.64 P/Share
|
|
Sep 11
2024
|
Paul J Diaz President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-1.51%
|
$390,000
$26.72 P/Share
|
|
Sep 11
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,100
-1.91%
|
$54,600
$26.17 P/Share
|
|
Sep 09
2024
|
Heinrich Dreismann Director |
SELL
Open market or private sale
|
Direct |
10,000
-7.6%
|
$270,000
$27.05 P/Share
|
|
Sep 03
2024
|
Jennifer Lynne Fox Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,771
+50.0%
|
-
|
|
Sep 03
2024
|
Colleen F Reitan Director |
SELL
Open market or private sale
|
Direct |
46,012
-51.96%
|
$1,242,324
$27.95 P/Share
|
|
Aug 25
2024
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
217
-0.49%
|
$6,076
$28.12 P/Share
|
|
Aug 21
2024
|
Margaret Ancona SVP, Chief of Staff |
SELL
Open market or private sale
|
Direct |
11,538
-12.69%
|
$311,526
$27.82 P/Share
|
|
Aug 19
2024
|
Rashmi Kumar Director |
SELL
Open market or private sale
|
Direct |
7,500
-8.83%
|
$210,000
$28.01 P/Share
|
|
Aug 13
2024
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
73,788
-3.51%
|
$2,066,064
$28.18 P/Share
|